In 2015, the SCALE study demonstrated that the GLP-1 analogue Liraglutide (3.0 mg weekly) results in 8.0% body weight loss [49], and a mean HbA1c reduction of 1.1% [50] after 56 weeks
Early studies suggest that these drugs may lower cravings and use for alcohol, tobacco, and even opioids
Common side effects of Semaglutide include nausea, vomiting, diarrhea, stomach pain, and constipation
Full SOUL phase 3b trial results: nej.md/4hHII5M @ACCinTouch Presented at #ACC25: Among participants with type 2 diabetes and cardiovascular disease, chronic kidney disease, or both, oral semaglutide (14 mg) was associated with a lower risk of cardiovascular events than placebo after 4 years of follow-up
Lysosomal acid lipase-deficient mice: depletion of white and brown fat, severe hepatosplenomegaly, and shortened life span
Available for a limited time this fall and winter